Evolution and immediate future of US screening guidelines (Q38203982)

31 August 2017

title

Evolution and immediate future of US screening guidelines (English)

1 reference

31 August 2017

Kirsten L Greene

1

1 reference

31 August 2017

Sanoj Punnen

series ordinal

2

1 reference

31 August 2017

Peter R Carroll

series ordinal

3

1 reference

31 August 2017

language of work or name

1 reference

1 May 2014

1 reference

Urologic Clinics of North America

31 August 2017

published in

1 reference

31 August 2017

volume

41

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

229-235

1 reference

The emergence of clinical practice guidelines

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Prostate-cancer mortality at 11 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Incidence of prostate cancer after termination of screening in a population-based randomised screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Alternative prostate cancer screening strategies--in response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2014.01.005

10.1016/J.UCL.2014.01.005

7 January 2021

Identifiers

DOI

1 reference

31 August 2017

1 reference